The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.
Raz MutaiIryna KuchukAlexandra GoldshteinRinat YerushalmiOfer RotemAdi Maisel LotanTali Bdolah-AbramAlberto GabizonHadar GoldvaserPublished in: Breast cancer research and treatment (2024)
Compared to wild-type, gBRCA carriers with locally advanced TNBC treated with neoadjuvant chemotherapy containing carboplatin had a higher pCR rate and better outcomes. These results strengthen the contention that gBRCA status should be considered when tailoring treatment decisions in women with locally advanced TNBC.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- phase ii study
- rectal cancer
- wild type
- squamous cell carcinoma
- radiation therapy
- sentinel lymph node
- dna repair
- randomized controlled trial
- metabolic syndrome
- dna methylation
- gene expression
- clinical trial
- oxidative stress
- dna damage
- phase iii
- glycemic control
- weight loss
- double blind
- placebo controlled